Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Etranacogene dezaparvovec - CSL Behring

Next Previous
X
Search
Drug Profile

Etranacogene dezaparvovec - CSL Behring

Alternative Names: AAV5-FIX-Padua; AAV5-hFIXco-Padua; AMT 061; CSL-222; Etranacogene dezaparvovec - CSL Behring/uniQure; Etranacogene dezaparvovec-drlb; EtranaDez; HEMGENIX; Lanacogene vosiparvovec

Latest Information Update: 19 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator uniQure
  • Developer CSL Behring
  • Class Antihaemorrhagics; Gene therapies
  • Mechanism of Action Factor IX replacements; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia B
  • New Molecular Entity No

Highest Development Phases

  • Marketed Haemophilia B

Most Recent Events

  • 16 Jul 2024 CSL Behring announces that the Canadian Agency for Drugs and Technologies in Health (CADTH) recommends public drug plan reimbursement for etranacogene dezaparvovec (HEMGENIX®) for the treatment of adults with hemophilia B
  • 15 Mar 2024 Registered for Haemophilia B in Australia (IV)
  • 28 Feb 2024 UniQure owns a patent family, including patents and patent applications, directed to the use of the Padua mutation in human Factor IX (“hFIX”) for gene therapy in etranacogene dezaparvovec

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top